Compare Flux Power Holdings Inc (FLUX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Moderna, Inc. — how do they compare? Flux Power Holdings Inc trades at $0.55 (market cap $11.23M), while Moderna, Inc. trades at $63.7 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 2153.2× Flux Power Holdings Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Flux Power Holdings Inc nearer its low. Which is the better fit depends on your goals.
| FLUX | MRNA | |
|---|---|---|
Market Cap | $11.23M | $24.18B |
Sector | Utilities | Health |
52-Week High | $6.66 | $81.80 |
52-Week Low | $0.51 | $22.36 |
Enterprise Value | $17.39M | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.5702, up 8.82% today, but technical indicators signal a bearish trend with moving averages and ADX showing sell signals. The company reported mixed quarterly results, missing EPS estimates in Q3 2025 and Q1 2026 while beating in Q4 2025. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 6 buy ratings. Recent developments include the upcoming Q4 2026 earnings call and the launch of SkyEMS 3.0 with AI-powered fleet insights.
FLUX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish sentiment from Wall Street contrasts with persistent losses and negative ROE/ROA. Key catalysts include execution on new product launches and path to profitability, while risks involve sustained cash burn and competitive pressure in clean energy storage.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
